Ketamine pharmaceuticals providerPharmaTher Holdings Ltd. (OTCQB:PHRRF)has been granted aNotice of Allowance by the U.S. Patent and Trademark Office (USPTO)for its "Compositions and Methods for Treating Motor Disorders" patent, intended to coverpotential ketamine treatment of Parkinson's disease and motor disorderscausing involuntary or uncontrollable body actions.
PharmaTher signed an exclusive license agreement with theUniversity of Arizonato develop and commercialize the patent in August 2020. The results from the clinical study of ketamine for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's would be made available in late-Q3 2022.
More...